{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:33:31Z","timestamp":1787315611781,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"\n Introduction<\/jats:title>\n \n Eravacycline (ERV) is a novel synthetic fluorocycline antibiotic with broad-spectrum antibacterial efficacy against pathogens. This study aimed to investigate the clinical effectiveness of eravacycline and its correlation with minimum inhibitory concentrations (MICs) against infections caused by\n Acinetobacter baumannii<\/jats:italic>\n or\n Klebsiella pneumoniae<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This retrospective multicenter study investigated the real-world use of ERV in 1,796 adults with infection caused by\n A. baumannii<\/jats:italic>\n or\n K. pneumoniae<\/jats:italic>\n in China. Antimicrobial susceptibility of strains and laboratory test results during treatment were analyzed. Microbiological and clinical outcomes were assessed at the end of treatment and day 30.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The overall susceptibility rate to ERV was 96.0% (1,027\/1,070), and around 98% of carbapenem-resistant isolates were susceptible to ERV. ERV had a 4-fold lower MIC\n 90<\/jats:sub>\n than tigecycline against both pathogens. At end of treatment, treatment success (microbiological eradication or clinical resolution) occurred in 82.6% (1,483\/1,796) of the cohort with microbiological eradication achieved 76.1% (789\/1,037). At day 30, infection cure was achieved in 83.57% (1,501\/1,796) of the cases. Different ERV regimens (monotherapy or concomitant therapy) had no influence on the treatment and 30-day clinical outcomes. Multivariable analysis identified that elevated C-reactive protein (CRP) levels during treatment, bloodstream infection, sepsis and specific clinical interventions (e.g., central venous catheterization) were independent predictors of treatment failure.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The study highlights ERV\u2019s utility in infection of\n A. baumannii<\/jats:italic>\n or\n K. pneumoniae<\/jats:italic>\n , especially carbapenem-resistant strains.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1746200","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:58:19Z","timestamp":1772607499000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world effectiveness and predictors of treatment failure for eravacycline in patients with Acinetobacter baumannii or Klebsiella pneumoniae infections: a multicenter retrospective analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yi","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaolian","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minya","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/phar.2366","article-title":"Evaluation of eravacycline: A novel fluorocycline","volume":"40","author":"Alosaimy","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9030119","article-title":"Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen","volume":"9","author":"Ayoub Moubareck","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv. Drug Delivery Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14787210.2024.2397663","article-title":"Efficacy and safety of eravacycline (ERV) in treating infections caused by Gram-negative pathogens: a systematic review and meta-analysis","volume":"22","author":"Chen","year":"2024","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jgar.2021.02.009","article-title":"Efficacy and safety of eravacycline: A meta-analysis","volume":"24","author":"Eljaaly","year":"2021","journal-title":"J. Glob Antimicrob. Resist."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.2147\/IDR.S515207","article-title":"Efficacy and safety of eravacycline combination therapy for carbapenem-resistant acinetobacter baumannii pneumonia in ICU patients: A retrospective study","volume":"18","author":"Guo","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"B10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrmicro.2017.148","article-title":"Uncovering the mechanisms of Acinetobacter baumannii virulence","volume":"16","author":"Harding","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02351-23","article-title":"Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S","volume":"12","author":"Kunz Coyne","year":"2024","journal-title":"Reg 2018 to 2022. Microbiol. Spectr."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060866","article-title":"The efficacy and safety of eravacycline in the treatment of complicated intra-abdominal infections: A systemic review and meta-analysis of randomized controlled trials","volume":"8","author":"Lan","year":"2019","journal-title":"J. Clin. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"127839","DOI":"10.1016\/j.micres.2024.127839","article-title":"Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat","volume":"288","author":"Lei","year":"2024","journal-title":"Microbiol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"210.e211","DOI":"10.1016\/j.cmi.2016.11.020","article-title":"MALDI-TOF\/MS identification of species from the Acinetobacter baumannii (Ab) group revisited: inclusion of the novel A. seifertii and A. dijkshoorniae species","volume":"23","author":"Mar\u00ed-Almirall","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.935343","article-title":"The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis","volume":"9","author":"Meng","year":"2022","journal-title":"Front. Med. (Laus)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01699-19","article-title":"In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1086\/430382","article-title":"Pilot study evaluating C-reactive protein levels in the assessment of response to treatment of severe bloodstream infection","volume":"40","author":"P\u00f3voa","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcrc.2017.05.007","article-title":"Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics - results from the BioVAP study","volume":"41","author":"P\u00f3voa","year":"2017","journal-title":"J. Crit. Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: A review in complicated intra-abdominal infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1177\/10600280221085551","article-title":"Efficacy of eravacycline versus best previously available therapy for adults with pneumonia due to difficult-to-treat resistant (DTR) acinetobacter baumannii","volume":"56","author":"Scott","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii","volume":"51","author":"Seifert","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1751143714564816","article-title":"Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient","volume":"16","author":"Shah","year":"2015","journal-title":"J. Intensive Care Soc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: A randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg."},{"key":"B24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00488-20","article-title":"Nonclinical pharmacokinetics, protein binding, and elimination of KBP-7072, an aminomethylcycline antibiotic, in animal models","volume":"64","author":"Tan","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40121-020-00351-0","article-title":"A real-world assessment of clinical outcomes and safety of eravacycline: A novel fluorocycline","volume":"9","author":"Van Hise","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s12879-019-4093-1","article-title":"In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Infect. Dis."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1746200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:58:20Z","timestamp":1772607500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1746200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":29,"alternative-id":["10.3389\/fcimb.2026.1746200"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1746200","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1746200"}}